Shopping Cart
Remove All
Your shopping cart is currently empty
Visugromab
Copy Product Info
😃Good
Catalog No. T80863Cas No. 2556646-63-8
Alias CTL-002, CTL002
Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15. Visugromab exhibits synergistic anticancer activity with the anti-PD1 antibody Nivolumab, making it suitable for PD-1/PD-L1 recurrent/refractory metastatic solid tumours.
Visugromab
Visugromab
Copy Product Info😃Good
Purity: 95%
Catalog No. T80863Alias CTL-002, CTL002Cas No. 2556646-63-8
Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15. Visugromab exhibits synergistic anticancer activity with the anti-PD1 antibody Nivolumab, making it suitable for PD-1/PD-L1 recurrent/refractory metastatic solid tumours.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $647 | - | In Stock | |
| 10 mg | $987 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:98.8% (SDS-PAGE); 97.5% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15. Visugromab exhibits synergistic anticancer activity with the anti-PD1 antibody Nivolumab, making it suitable for PD-1/PD-L1 recurrent/refractory metastatic solid tumours. |
| In vivo | In preclinical toxicology studies on cynomolgus monkeys, Visugromab (maximum dose of 100 mg/kg, weekly) did not exhibit any signs of toxicity. [2] |
| Synonyms | CTL-002, CTL002 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | GDF15/MIC1 |
| Molecular Weight | 144.50 kDa |
| Cas No. | 2556646-63-8 |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Visugromab | purchase Visugromab | Visugromab cost | order Visugromab | Visugromab in vivo | Visugromab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.